1,743 reports of this reaction
3.6% of all PALIPERIDONE PALMITATE reports
#3 most reported adverse reaction
HOSPITALISATION is the #3 most commonly reported adverse reaction for PALIPERIDONE PALMITATE, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,743 FDA adverse event reports linking PALIPERIDONE PALMITATE to HOSPITALISATION. This represents approximately 3.6% of all 48,953 adverse event reports for this drug.
PALIPERIDONE PALMITATE has an overall safety score of 85 out of 100. Patients taking PALIPERIDONE PALMITATE who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is moderately reported among PALIPERIDONE PALMITATE users, representing a notable but not dominant share of adverse events.
In addition to hospitalisation, the following adverse reactions have been reported for PALIPERIDONE PALMITATE:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 1,743 FDA reports for PALIPERIDONE PALMITATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 3.6% of all adverse event reports for PALIPERIDONE PALMITATE, making it one of the most commonly reported side effect.
If you experience hospitalisation while taking PALIPERIDONE PALMITATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.